Arcturus Therapeutics is trading 11.41% up now at $17.38, with the move primarily supported by biotechnology-sector strength; XBI is up 2.55%.
- No new company-specific announcement was identified for September 17, 2026.
- A broader market rebound followed the Federal Reserve decision.
- Near-term optimism around ARCT-810 Phase II data expected later in September may also support sentiment, but this is not a new catalyst.